Baseline Characteristics of Patients in a Phase 3, Randomized, Placebo-Controlled Trial of Admilparant (BMS-986278), an Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Progressive Pulmonary Fibrosis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1609; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • P3 data • Immunology • Pulmonary Disease • Respiratory Diseases
|